MicroPort CardioFlow Medtech Corporation announced that with effect from August 29, 2023: Dr. Luo Qiyi has resigned as a non-executive Director, the Chairman, the chairman of Nomination Committee, a member of Remuneration Committee, an Authorized Representative and a director and the chairman of MP CardioFlow; Mr. Chen Guoming has resigned as President of MP CardioFlow and re-designated from an executive Director to a non-executive Director, and has been appointed as the Chairman, the chairman of Nomination Committee, a member of Remuneration Committee, an Authorized Representative and the chairman of MP CardioFlow; and Mr. Jeffrey R Lindstrom has been appointed as an executive Director, President, and a director of MP CardioFlow. Mr. Chen, aged 38, joined the Group as a vice president on September 1, 2016 and was mainly responsible for research and development ("R&D") since then and participating in the management and strategic development of Group. He served as an executive Director, President and director and general manager of MP CardioFlow from September 29, 2020 to August 29, 2023.

Mr. Chen focused on research and development, clinical application and supply chain management of devices in the field of valves for more than 10 years. Before joining the Company in September 2016, Mr. Chen joined the group of MicroPort Scientific Corporation in March 2010 and worked as senior R&D manager at Shanghai MicroPort Medical (Group) Co. Ltd. from March 2010 to August 2016.

Mr. Chen obtained a bachelor's degree in engineering mechanics from Shanghai Jiao Tong University in China in June 2007 and a master's degree in mechatronics engineering from Shanghai Jiao Tong University in China in March 2010. He is also the inventor or a co-inventor of over 100 invention patents in China and overseas as of the date of this announcement. Mr. Lindstrom, aged 57, joined Group in January 2022 as the vice president (R&D) of Company.

He has over 25 years R&D experience in the minimally invasive interventional medical device industry. Prior to joining the Group, he served as senior director of engineering in Edwards Lifesciences Corporation (New York Stock Exchange ticker symbol: EW) since 2012, where he was responsible for developing the R&D strategy, directing and managing the R&D activities, overseeing the full product development lifecycle, leading the development and commercialization of the electro-mechanical transcatheter heart valve system and leading the development and clinical evaluation of the embolic protection system. From 2008 to 2012, he served as R&D director of The Spectranetics Corporation.

From 1998 to 2006, he served as R&D manager of Abbott Vascular (formerly known as Guidant Corporation). Mr. Lindstrom obtained his bachelor's degree in chemical engineering from Illinois Institute of Technology in the United States in 1996. He also obtained the certificate of general management from UCLA Anderson School of Management in the United States in 2016.

He owns six patents relating to the cardiovascular medical devices.